Clinical trial
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest…
NCT00434473 · Anthera Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00434473 |
|---|---|
| Title | IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome |
| Official title | IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis) |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome |
| Intervention type | Drug, Other |
| Interventions | A-001, Placebo |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Feb 13, 2007 |
| Last update posted | Mar 4, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: